Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT00669188
Other study ID # 080122
Secondary ID 08-HG-0122
Status Completed
Phase N/A
First received
Last updated
Start date April 24, 2008
Est. completion date July 8, 2020

Study information

Verified date January 9, 2024
Source National Institutes of Health Clinical Center (CC)
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Summary: A few studies have explored factors which influence patient-provider communication in a controlled setting. However, more information is needed about how different factors affect communication so that it can be improved. Third- and fourth-year medical students may be eligible for this study. Participants are recruited from the Washington, D.C. area. At the research center, participants will use a virtual reality headset to view a virtual clinic environment and interact with a virtual patient. After interacting with the virtual patient, participants will complete a questionnaire about their experience within the virtual clinic and other research-related information. The total time for the study visit is 60 minutes. Eligibility: Third- and fourth-year medical students at least 18 years of age. You may not take part in the study if you have a history of seizures and/or are pregnant.


Description:

This study will investigate research questions regarding factors influencing patient-provider communication. Participants will interact with a virtual patient in a virtual clinical setting. Third- or fourth-year medical students may be eligible for this study. Participants are recruited from the Washington, D.C. area. Study participants will perform one task and complete one set of questions at the study appointment. The task involves viewing a virtual patient s health information and interacting with the virtual patient in a virtual environment clinical scenario. While in the virtual environment, the subject wears a head-mounted video unit that allows him or her to see elements of the environment. The activities in the virtual environment take about 15 minutes. The total time for the study is about 60 minutes.


Recruitment information / eligibility

Status Completed
Enrollment 326
Est. completion date July 8, 2020
Est. primary completion date July 8, 2020
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility - INCLUSION CRITERIA: Healthy adult volunteers who are third or fourth-year medical students. Both men and women over age 18 will be eligible for this study (though in practice the age range is likely to naturally be constrained by the typical age of medical students). EXCLUSION CRITERIA: 1) persons with seizure or vestibular disorders; 2) women with known pregnancy; 3) persons who are highly prone to motion sickness; 4) those with low, uncorrected vision or hearing; 5) all current and past employees and contractors of NHGRI; and 6) persons who have received information about the study purpose or procedure from a past participant.

Study Design


Related Conditions & MeSH terms


Intervention

Other:
Information absent
Information
Information
Information

Locations

Country Name City State
United States National Institutes of Health Clinical Center Bethesda Maryland

Sponsors (1)

Lead Sponsor Collaborator
National Human Genome Research Institute (NHGRI)

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary treatment recommendations recommendations made for the virtual patient's treatment at time of study
See also
  Status Clinical Trial Phase
Completed NCT06326723 - Investigate the PK, Safety, and Tolerability After Single and Multiple Dose Daridorexant in Chinese Healthy Subjects Phase 1
Recruiting NCT00001367 - Diagnosis and History Study of Patients With Different Neurological Conditions
Completed NCT02699710 - Effect of Food, Rabeprazole, Methotrexate and Formulation on the Pharmacokinetics (PK) of GDC-0853 and the Effect of GDC-0853 on the PK of Methotrexate in Healthy Subjects Phase 1
Completed NCT02231892 - Repetitive Transcranial Magnetic Stimulation Equipment Testing and Pilot Study N/A
Not yet recruiting NCT06441916 - Bioequivalence Study of Dabigatran Etexilate Capsules 150 mg in Healthy Thai Volunteers Under Fasting Conditions Phase 1
Completed NCT03771586 - A Study to Assess the Electrophysiology, Safety, Tolerability, and Pharmacokinetics of SAGE-718 Using a Ketamine Challenge in Healthy Subjects Phase 1
Not yet recruiting NCT06337422 - Bioequivalence Study of Generic Celecoxib 200 mg Capsules Phase 1
Completed NCT03302182 - Bioequivalence Study of Ritonavir Versus NORVIR in Healthy Chinese Subjects Phase 1
Completed NCT05049343 - Study of SAGE-904 Using a Ketamine Challenge to Evaluate Electrophysiology, Safety, Tolerability, and Pharmacokinetics in Healthy Participants Phase 1
Recruiting NCT01629108 - Normal Values in Hearing and Balance Testing
Completed NCT02947854 - Study to Assess Safety, Tolerability and Immune Response of Fimaporfin-induced Photochemical Internalisation of Antigen/Adjuvant Phase 1
Completed NCT02534870 - Pharmacokinetics and Safety of the Co-administration of ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) and ABT-333 in Healthy Chinese Subjects Phase 1
Completed NCT02224053 - Drug-Drug Interaction Study With AZD9291 and Omeprazole in Healthy Volunteers Phase 1
Completed NCT01684891 - A 28-Day Pharmacokinetics Study of RG1662 in Healthy Male Volunteers Phase 1
Completed NCT01711762 - A Pharmacokinetics Study of Radioactive-Labeled GDC-0973 in Healthy Male Volunteers Phase 1
Completed NCT01676584 - A Study of Single Dose RO6811135 in Healthy Volunteers Phase 1
Completed NCT01697436 - A Bioequivalence Study of an Oral Solution of Copegus (Ribavirin) Compared to Copegus Tablets Phase 1
Completed NCT01414881 - Study to Assess the Effects of Mipomersen on Lipid and Lipoprotein Metabolism in Healthy Subjects Phase 1
Completed NCT01433575 - A Pharmacokinetic Study of RO4917838 in Healthy Chinese Volunteers Phase 1
Completed NCT01461967 - A Study on Safety, Pharmacokinetics and Pharmacodynamics of RO5508887 in Healthy Volunteers Phase 1